Antengene Corporation Limited, a leading innovative commercial-stage global biotech company focused on discovering, developing, and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors, and hematological malignancies, has announced a significant milestone in the Asia Pacific region. South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) after one prior therapy. This approval took effect on March 1, 2026, marking the second indication for XPOVIO® to receive reimbursement in South Korea.

This development is crucial for pharmaceutical executives, R&D heads, and regulatory teams operating in the Asian market, as it enhances patient access to innovative therapies and strengthens Antengene's commercial footprint. XPOVIO® is the first XPO1 inhibitor to be approved for reimbursement by South Korea's NHIS for multiple myeloma treatment. In South Korea, the drug has now been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), with two of these included in the national reimbursement scheme. The first reimbursed indication covers XPOVIO® in combination with dexamethasone for relapsed or refractory MM patients who have received at least four prior therapies.

With expanded reimbursement coverage, XPOVIO® is poised to benefit a broader patient population, contributing significantly to the management of hematological malignancies in South Korea. XPOVIO® features a novel mechanism of action as the world's first approved orally-available, selective XPO1 inhibitor. To date, it has been approved in ten countries and regions in the APAC area, including mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia. Notably, it has been included in national insurance schemes in five markets: mainland China, Taiwan, Australia, Singapore, and now South Korea with this second indication.

Antengene's strategic push to expand XPOVIO®'s access across APAC underscores its commitment to addressing unmet medical needs in oncology. This reimbursement approval not only validates the clinical efficacy and safety profile of XPOVIO® but also highlights the growing recognition of innovative biotech therapies in national health systems. For CRO/CMO leaders and supply chain professionals, this could signal increased demand for manufacturing and logistics support tailored to hematological treatments. Procurement teams may need to prepare for potential scale-up in API sourcing and formulation processes specific to XPO1 inhibitors.

Antengene's broader pipeline further positions it as a key player in Asian biotech. The company has developed in-house programs such as ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor). Additionally, its proprietary AnTenGager™ T cell engager 2.0 platform supports broad applicability across autoimmune diseases, solid tumors, and hematological malignancies, with multiple programs targeting various CD3 combinations for cancers like ovarian, kidney, lung, colorectal, multiple myeloma, and leukemia. Antengene has secured 32 investigational new drug (IND) approvals in the U.S. and Asia, and new drug application (NDA) approvals in 10 APAC markets.

This reimbursement news comes at a time when regulatory compliance and health insurance integrations are pivotal for market penetration in Asia. For manufacturing managers, it emphasizes the importance of scalable production for approved indications, while technology vendors in pharmaceutical instrumentation and quality assurance can anticipate partnerships for ensuring compliance with NHIS standards. Leadership changes or strategic insights from Antengene, listed on SEHK: 6996.HK, may influence investor confidence and further M&A activities in the region.

Looking ahead, Antengene plans to pursue broader access for XPOVIO® across additional APAC markets, potentially driving economic and regional development in pharmaceutical outsourcing and contract services. This aligns with trends in pharmaceutical supply chain solutions and legislation/regulatory compliance, offering strategic opportunities for stakeholders. Forward-looking statements indicate ongoing commitment, though subject to risks outlined in annual reports. Overall, this approval reinforces Antengene's role in advancing B2B pharmaceutical tech innovations in Asia, benefiting executives focused on hematological malignancies treatments and insurance reimbursements.

In summary, the dual reimbursement status of XPOVIO® in South Korea exemplifies successful navigation of regulatory landscapes, paving the way for enhanced commercial operations and patient outcomes in the region. (Word count: 612)